Evaluating the effects of antiplatelet and antioxidant medications on eye health in patients with dry AMD
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
This study is testing if low doses of antiplatelet medications, with or without antioxidants, can help people with dry age-related macular degeneration keep their eyesight and slow down the growth of drusen.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 174 (estimated) |
| Ages | 50 Years to 85 Years |
| Sex | All |
| Sponsor | Navamindradhiraj University Academic / other |
| Locations | 1 site (Bangkok, Dusit) |
| Trial ID | NCT06165068 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the impact of low doses of antiplatelet medications, specifically aspirin and clopidogrel, combined with or without antioxidants like N-acetylcysteine, on the progression of drusen in patients with dry age-related macular degeneration (AMD). Participants will be divided into three groups: those already on antiplatelet therapy, those receiving antiplatelet therapy plus antioxidants, and those not using any medications. The study will monitor changes in drusen size and visual acuity using advanced imaging techniques and clinical evaluations.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50-85 with dry AMD and at least one large drusen.
Not a fit: Patients with advanced AMD or other significant retinal diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new insights into managing dry AMD and potentially slow down its progression.
How similar studies have performed: While there have been studies on the effects of antiplatelet agents in other conditions, this specific combination approach in dry AMD is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron. * Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity. * Age range: 50-85 years * Patients who have previously used antiplatelet drugs. Exclusion Criteria: * Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization) * Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema. * Patient with a history of intravitreal anti-VEGF injection or macular laser. * Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.
Where this trial is running
Bangkok, Dusit
- Department of ophthalmology, Faculty of medicine, Vajira hospital, Navamindradhiraj University — Bangkok, Dusit, Thailand (Recruiting)
Study contacts
- Study coordinator: Yolradee Winuntamalakul
- Email: yolradee.win@nmu.ac.th
- Phone: +66851283362
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.